BAOLINGBAO BIOLOGY CO., LTD. – Trademark Portfolio
Entity Type: 99
BAOLINGBAO BIOLOGY CO., LTD. owns a portfolio of 7 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), including well-known marks such as ERYFINE, ALLINKLE, IMORAWEL, and VELFIBRA. Of these, 4 are registered and 1 is pending. The portfolio spans 3 Nice Classification classes, led by Class 5 (Pharmaceuticals) and Class 30 (Staple Foods). Headquartered in DEZHOU.
NO.1, DONGWAIHUAN ROAD, NATIONAL LEVEL
HI-TECH DEVELOPMENT ZONE(YUCHENG)
DEZHOU 999001 , CN
Showing of trademarks Trademarks
Trademark Classifications
BAOLINGBAO BIOLOGY CO., LTD.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Coffee, tea, cocoa and artificial coffee; rice; tapioca and sago; flour and preparations
Frequently Asked Questions
How many trademarks does BAOLINGBAO BIOLOGY CO., LTD. have?
BAOLINGBAO BIOLOGY CO., LTD. has 7 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 pending, 1 abandoned, 1 cancelled.
What trademark classes does BAOLINGBAO BIOLOGY CO., LTD. file in?
BAOLINGBAO BIOLOGY CO., LTD. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 30 (Staple Foods), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are BAOLINGBAO BIOLOGY CO., LTD.'s most well-known trademarks?
BAOLINGBAO BIOLOGY CO., LTD.'s registered trademark portfolio includes well-known marks such as ERYFINE, ALLINKLE, IMORAWEL, and VELFIBRA. These are among 4 currently registered trademarks in the portfolio.
What is BAOLINGBAO BIOLOGY CO., LTD.'s trademark registration success rate?
BAOLINGBAO BIOLOGY CO., LTD. has a 67% trademark registration rate, with 4 out of 6 resolved applications resulting in successful registration. Currently, 1 application is pending review.